ERBB2 and breast cancer: The DESTINY-Breast04 trial led to the approval of T-DXd by the USA Food and Drug Administration (FDA) and by EMA (European Medicines Agency) for patients with pretreated HER2-low metastatic BC who have received at least one prior line of CT [109,110].